Art. -Nr.: HY-N2440

Gypenoside A

Name: Gypenoside A
Brand: MedChemExpress
SKU: HY-N2440
Price: 62.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Gypenoside A is an orally active triterpenoid compound that can be isolated from Gynostemma pentaphyllum. Gypenoside A has anti-inflammatory and antioxidant activities. Gypenoside A also has a certain protective effect on cardiomyocytes and can inhibit apoptosis. Gypenoside A can be used in the research of cardiovascular diseases and inflammation-related diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.79%
CAS. Nr.: 157752-01-7
Formel: C₄₆H₇₄O₁₇
Molecular Weight:899.07

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Gypenoside A Chemical Structure

CAS. Nr.: 157752-01-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

FOXO1

IL-6

IL-13

IL-5

IL-4

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle AMPK Isoform-spezifische Produkte anzeigen :

Alle FOXO Isoform-spezifische Produkte anzeigen :

FOXO1
FOXO3

Alle COX Isoform-spezifische Produkte anzeigen :

In Vitro

Gypenoside A (0-10 μM; 24 h) can reduce the secretion of cytokines and chemokines and inhibit the production of ROS in TNF-α/IL-4-treated BEAS-2B cells^[1].
Gypenoside A (10-20 μM; 24 h) can increase cell viability and inhibit apoptosis in OGD/R-treated H9c2 cells. The mechanism involves the activation of the AMPK/Foxo1 signaling pathway and a decrease in the expression level of miR-143-3p^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

Oxygen-glucose deprivation/re-oxygenation (OGD/R) treated H9c2 cells
Concentration:

10 and 20 μM
Incubation Time:

24 h
Result:

Restored the levels of p-AMPK and p-Foxo1.

In Vivo

Gypenoside A (10-30 mg/kg; intraperitoneal injection; single dose) has an improving effect in a mouse asthma model^[1].
Gypenoside A (100 mg/kg; gavage; single dose) can improve hemodynamic parameters, reduce apoptosis and infarct area in myocardial tissue in a rat myocardial ischemia/reperfusion injury model^[2].
Pharmacokinetic Analysis in Rats^[3]

Route	Dose (mg/kg)	AUC_(0-t) (ng/mL·h)	AUC_(0-∞) (ng/mL·h)	t_1/2z (h)	CL_z/F (L/h/kg)	V_z/F (L/kg)	C_max (ng/mL)
p.o.	5	14.9	15.9	1.4	319.9	665.4	8.6
i.v.	1	332.9	334.3	0.8	3.0	3.3	621.9

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c mice aged 6 weeks old treated AlOH₃ and 50 OVA^[1]
Dosage:

10 and 30 mg/kg
Administration:

Intraperitoneal injection; single dose
Result:

Significantly reduced eosinophil infiltration in the lungs and tracheal goblet cell hyperplasia.
Mitigated airway hyperresponsiveness.
Decreased the levels of cytokines and chemokines in BALF, such as IL-4, IL-5, IL-13, TNF-α, IL-6, CCL11, and CCL24, while elevated IFN-γ levels.
Reduced OVA-IgE and OVA-IgG1 levels and increased OVA-IgG2a levels in serum.
Decreased IL-4, IL-5, and IL-13 levels and increased IFN-γ secretion in splenocytes.
Promoted GSH and suppressed MDA activity, and reduced TNF, IL6, and COX2 expression in the lungs.

Chemical Information

CAS. Nr. 157752-01-7
Appearance Solid
Molecular Weight 899.07
Formel C₄₆H₇₄O₁₇
Color White to off-white
SMILES

O=CC12C3C(C4(C(C(C5(CC(/C=C(C)/C)OC5O)O)CC4)CC3)C)(CCC1C(C)(C(OC6C(C(C(O)CO6)OC7C(C(C(O)CO7)O)O)OC8C(C(C(O)C(C)O8)O)O)CC2)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Chin Med

Gynostemma Pentaphyllum ameliorates CCl4-induced liver injury via PDK1/Bcl-2 pathway with comprehensive analysis of network pharmacology and transcriptomics. [Abstract]

2024 May 15;19(1):70. PMID: 38750545

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (111.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1123 mL

5.5613 mL

11.1226 mL

5 mM

0.2225 mL

1.1123 mL

2.2245 mL

10 mM

0.1112 mL

0.5561 mL

1.1123 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang WC, et al. Gypenoside A from Gynostemma pentaphyllum Attenuates Airway Inflammation and Th2 Cell Activities in a Murine Asthma Model. Int J Mol Sci. 2022 Jul 12;23(14):7699. [Content Brief]

[2]. Chang L, et al. Gypenoside A protects ischemia/reperfusion injuries by suppressing miR-143-3p level via the activation of AMPK/Foxo1 pathway. Biofactors. 2020 May;46(3):432-440. [Content Brief]

[3]. He Y, et al. Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability. Int J Anal Chem. 2022 Aug 12;2022:6734408. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1123 mL	5.5613 mL	11.1226 mL	27.8065 mL
	5 mM	0.2225 mL	1.1123 mL	2.2245 mL	5.5613 mL
	10 mM	0.1112 mL	0.5561 mL	1.1123 mL	2.7807 mL
	15 mM	0.0742 mL	0.3708 mL	0.7415 mL	1.8538 mL
	20 mM	0.0556 mL	0.2781 mL	0.5561 mL	1.3903 mL
	25 mM	0.0445 mL	0.2225 mL	0.4449 mL	1.1123 mL
	30 mM	0.0371 mL	0.1854 mL	0.3708 mL	0.9269 mL
	40 mM	0.0278 mL	0.1390 mL	0.2781 mL	0.6952 mL
	50 mM	0.0222 mL	0.1112 mL	0.2225 mL	0.5561 mL
	60 mM	0.0185 mL	0.0927 mL	0.1854 mL	0.4634 mL
	80 mM	0.0139 mL	0.0695 mL	0.1390 mL	0.3476 mL
	100 mM	0.0111 mL	0.0556 mL	0.1112 mL	0.2781 mL

Bioz

Keywords

Gypenoside A

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Gypenoside A

Publications Citing Use of MedChemExpress (MCE) Gypenoside A

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Alle AMPK Isoform-spezifische Produkte anzeigen

Alle FOXO Isoform-spezifische Produkte anzeigen

Alle COX Isoform-spezifische Produkte anzeigen